Insights from pharmacokinetic models of host-microbiome drug metabolism

References

• Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34:401–431. doi:10.1007/s10928-007-9053-5.
   Google Scholar
• Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341:295–298. doi:10.1126/science.1235872.
   Google Scholar
• Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noël-Romas L, Grobler A, Westmacott G, Xie IY, Butler J, et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science. 2017;356:938–945. doi:10.1126/science.aai9383.
   Google Scholar
• Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019;364:eaau6323. doi:10.1126/science.aav6390.
   Google Scholar
• van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat Commun. 2019;10:310. doi:10.1038/s41467-019-08294-y.
   Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570:462–467. doi:10.1038/s41586-019-1310-4.
   Google Scholar
• Elmer GW, Remmel RP. Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica. 1984;14:829–840. doi:10.3109/00498258409151405.
   Google Scholar
• Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305:789–794. doi:10.1056/NEJM198110013051403.
   Google Scholar
• Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics. 1997;7:35–43. doi:10.1097/00008571-199702000-00005.
   Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019;363:eaat9931. doi:10.1126/science.aat9931.
   Google Scholar
• Ferl GZ, Theil F-P, Wong H. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Biopharm Drug Dispos. 2016;37:75–92. doi:10.1002/bdd.1994.
   Google Scholar
• Schmitt W, Willmann S. Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today Technol. 2004;1:449–456. doi:10.1016/j.ddtec.2004.09.006.
   Google Scholar
• Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14:273–287. doi:10.1038/nrmicro.2016.17.
   Google Scholar
• Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 2017;179:204–222. doi:10.1016/j.trsl.2016.08.002.
   Google Scholar
• Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017;356:eaag2770. doi:10.1126/science.aag2770.
   Google Scholar
• Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, Mani S, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831–835. doi:10.1126/science.1191175.
   Google Scholar
• Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44:D1075-9. doi:10.1093/nar/gkv1075.
   Google Scholar
• Pellock SJ, Redinbo MR. Glucuronides in the gut: sugar-driven symbioses between microbe and host. J Biol Chem. 2017;292:8569–8576. doi:10.1074/jbc.R116.767434.
   Google Scholar
• Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet. 2002;41:751–790. doi:10.2165/00003088-200241100-00005.
   Google Scholar
• Ilett KF, Tee LBG, Reeves PT, Minchin RF. Mebolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther. 1990;46:67–93. doi:10.1016/0163-7258(90)90036-2.
   Google Scholar
• Colburn WA, Bekersky I, Min BH, Hodshon BJ, Garland WA. Contribution of gut contents, intestinal wall and liver to the first-pass metabolism of clonazepam in the rat. Res Commun Chem Pathol Pharmacol. 1980;27:73–90.
   Google Scholar
• Hofmann AF, Cravetto C, Molino G, Belforte G, Bona B. Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism. Gastroenterology. 1987;93:693–709. doi:10.1016/0016-5085(87)90430-6.
   Google Scholar
• Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60:717–733. doi:10.1016/j.addr.2007.08.043.
   Google Scholar
• Ben GM, Thiele I. Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients. NPJ Syst Biol Appl. 2016;2:16013. doi:10.1038/npjsba.2016.13.
   Google Scholar
• Sier JH, Thumser AE, Plant NJ. Linking physiologically-based pharmacokinetic and genome-scale metabolic networks to understand estradiol biology. BMC Syst Biol. 2017;11:141. doi:10.1186/s12918-017-0520-3.
   Google Scholar
• Sahoo S, Haraldsdóttir HS, Fleming RMT, Thiele I. Modeling the effects of commonly used drugs on human metabolism. Febs J. 2015;282:297–317. doi:10.1111/febs.13128.
   Google Scholar
• Cordes H, Thiel C, Baier V, Blank LM, Kuepfer L. Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation. NPJ Syst Biol Appl. 2018;4:10. doi:10.1038/s41540-018-0048-1.
   Google Scholar
• Krauss M, Schaller S, Borchers S, Findeisen R, Lippert J, Kuepfer L. Integrating cellular metabolism into a multiscale whole-body model. PLoS Comput Biol. 2012;8:e1002750. doi:10.1371/journal.pcbi.1002750.
   Google Scholar
• Arnoldini M, Cremer J, Hwa T. Bacterial growth, flow, and mixing shape human gut microbiota density and composition. Gut Microbes. 2018:1–8. doi:10.1080/19490976.2018.1448741.
   Google Scholar
• Cremer J, Arnoldini M, Hwa T. Effect of water flow and chemical environment on microbiota growth and composition in the human colon. Proc National Acad Sci. 2017;114:6438–6443. doi:10.1073/pnas.1619598114.
   Google Scholar
• Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623–628. doi:10.1038/nature25979.
   Google Scholar
• Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, Kurilshikov A, Bonder MJ, Valles-Colomer M, Vandeputte D, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–564. doi:10.1126/science.aad3503.
   Google Scholar
• Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352:565–569. doi:10.1126/science.aad3369.
   Google Scholar
• Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: oral solutions. J Pharm Sci. 2011;100:5324–5345. doi:10.1002/jps.22726.
   Google Scholar
• Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. Population-based mechanistic prediction of oral drug absorption. Aaps J. 2009;11:225–237. doi:10.1208/s12248-009-9099-y.
   Google Scholar
• Kirchmair J, Göller AH, Lang D, Kunze J, Testa B, Wilson ID, Glen RC, Schneider G. Predicting drug metabolism: experiment and/or computation? Nat Rev Drug Discovery. 2015;14:387–404. doi:10.1038/nrd4581.
   Google Scholar
• Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discovery. 2005;4:825–833. doi:10.1038/nrd1876.
   Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23. doi:10.1007/s11095-004-9004-4.
   Google Scholar
• Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21:806–822. doi:10.2174/1381612820666141024151119.
   Google Scholar
• Hadadi N, MohammadiPeyhani H, Miskovic L, Seijo M, Hatzimanikatis V. Enzyme annotation for orphan and novel reactions using knowledge of substrate reactive sites. Proc National Acad Sci. 2019;116:7298–7307. doi:10.1073/pnas.1818877116.
   Google Scholar
• Klünemann M, Schmid M, Patil KR. Computational tools for modeling xenometabolism of the human gut microbiota. Trends Biotechnol. 2014;32:157–165. doi:10.1016/j.tibtech.2014.01.005.
   Google Scholar
• Sharma AK, Jaiswal SK, Chaudhary N, Sharma VK. A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota. Sci Rep. 2017;7:9751. doi:10.1038/s41598-017-10203-6.
   Google Scholar
• Jones H, Chen Y, Gibson C, Heimbach T, Parrott N, Peters S, Snoeys J, Upreti V, Zheng M, Hall S. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97:247–262. doi:10.1002/cpt.37.
   Google Scholar
• Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell. 2018;9:432–445. doi:10.1007/s13238-018-0547-2.
   Google Scholar